Iannone M A, Wolberg G, Zimmerman T P
Division of Experimental Therapy, Wellcome Research Laboratories, Research Triangle Park, NC 27709.
Biochem Pharmacol. 1991 Dec 11;42 Suppl:S105-11. doi: 10.1016/0006-2952(91)90399-p.
The cyclic adenosine-3',5'-monophosphate (cAMP) elevation caused by exposure of human neutrophils to the Ca2+ ionophore A23187 was prevented when endogenously produced adenosine was either removed by preincubation with adenosine deaminase or blocked from binding to the adenosine receptor by antagonists [theophylline or (E)-4-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-9H-purin-8-yl)cinnamic acid]. In the absence of endogenous adenosine, A23187 potentiated the neutrophil cAMP response to 2-chloroadenosine, prostaglandin E1, and isoproterenol. When neutrophil suspensions were preincubated with concentrations of Ro 20-1724, which appeared to maximally inhibit cAMP phosphodiesterase, A23187 was still able to substantially elevate cAMP levels, suggesting that A23187 increases cAMP by amplifying adenylate cyclase responsiveness to the agonist rather than by inhibiting cAMP phosphodiesterase. The ability of A23187 to augment the cAMP elevation caused by 2-chloroadenosine was persistent over a 10-min period. The neutrophil cAMP elevations caused by chemoattractants leukotriene B4, C5a, and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) were all prevented when endogenously produced adenosine was eliminated from the cell suspensions by the addition of adenosine deaminase. The A23187-induced cAMP elevation was inhibited completely by the calmodulin inhibitors chlorpromazine, trifluoperazine and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, whereas cAMP levels induced by FMLP, leukotriene B4 and C5a were less affected. It appears that A23187 raises cAMP in human neutrophils by a calmodulin-dependent potentiation of adenylate cyclase responsiveness to endogenously produced adenosine while the chemoattractant-induced cAMP elevations (FMLP), leukotriene B4, and C5a), although possibly Ca2+ dependent, are less sensitive to calmodulin inhibitors and may involve additional biochemical events.
当通过与腺苷脱氨酶预孵育去除内源性产生的腺苷,或通过拮抗剂[茶碱或(E)-4-(1,2,3,6-四氢-1,3-二甲基-2,6-二氧代-9H-嘌呤-8-基)肉桂酸]阻断其与腺苷受体的结合时,人中性粒细胞暴露于Ca2+离子载体A23187所引起的环磷酸腺苷(cAMP)升高被阻止。在没有内源性腺苷的情况下,A23187增强了中性粒细胞对2-氯腺苷、前列腺素E1和异丙肾上腺素的cAMP反应。当中性粒细胞悬液与似乎能最大程度抑制cAMP磷酸二酯酶的Ro 20-1724浓度预孵育时,A23187仍能显著提高cAMP水平,这表明A23187通过增强腺苷酸环化酶对激动剂的反应性而非通过抑制cAMP磷酸二酯酶来增加cAMP。A23187增强2-氯腺苷引起的cAMP升高的能力在10分钟内持续存在。当通过添加腺苷脱氨酶从细胞悬液中消除内源性产生的腺苷时,趋化因子白三烯B4、C5a和N-甲酰-L-甲硫氨酰-L-亮氨酰-L-苯丙氨酸(FMLP)引起的中性粒细胞cAMP升高均被阻止。A23187诱导的cAMP升高被钙调蛋白抑制剂氯丙嗪、三氟拉嗪和N-(6-氨基己基)-5-氯-1-萘磺酰胺完全抑制,而FMLP、白三烯B4和C5a诱导的cAMP水平受影响较小。似乎A23187通过钙调蛋白依赖性增强腺苷酸环化酶对内源性产生的腺苷的反应性来提高人中性粒细胞中的cAMP,而趋化因子诱导的cAMP升高(FMLP、白三烯B4和C5a)虽然可能依赖于Ca2+,但对钙调蛋白抑制剂不太敏感,可能涉及其他生化事件。